Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)

被引:27
|
作者
Talaei, Mohammad [1 ]
Faustini, Sian [2 ]
Holt, Hayley [1 ,3 ,4 ]
Jolliffe, David A. [1 ,3 ]
Vivaldi, Giulia [1 ,3 ]
Greenig, Matthew [1 ]
Perdek, Natalia [1 ]
Maltby, Sheena [1 ]
Bigogno, Carola M. [1 ]
Symons, Jane [5 ]
Davies, Gwyneth A. [6 ]
Lyons, Ronan A. [6 ]
Griffiths, Christopher J. [1 ,4 ]
Kee, Frank [7 ]
Sheikh, Aziz [8 ]
Richter, Alex G. [2 ]
Shaheen, Seif O. [1 ]
Martineau, Adrian R. [1 ,3 ,4 ]
机构
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Populat Hlth, London, England
[2] Univ Birmingham, Coll Med & Dent Sci, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
[3] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England
[4] Queen Mary Univ London, Asthma UK Ctr Appl Res, London, England
[5] Jane Symons Media, London, England
[6] Swansea Univ, Med Sch, Populat Data Sci, Singleton Pk, Swansea, W Glam, Wales
[7] Queens Univ Belfast, Ctr Publ Hlth Res NI, Belfast, Antrim, North Ireland
[8] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland
基金
英国科研创新办公室;
关键词
SARS-CoV-2; Serology; Ethnicity; Diet; Micronutrients; Lifestyle; Exercise; Obesity; Alcohol; Occupation; INFECTION;
D O I
10.1186/s12916-022-02286-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. Methods We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a positive swab test result for SARS-CoV-2 prior to enrolment. Information on 88 potential sociodemographic, behavioural, nutritional, clinical and pharmacological risk factors was obtained through online questionnaires, and combined IgG/IgA/IgM responses to SARS-CoV-2 spike glycoprotein were determined in dried blood spots obtained between November 6, 2020, and April 18, 2021. We used logistic and linear regression to estimate adjusted odds ratios (aORs) and adjusted geometric mean ratios (aGMRs) for potential determinants of SARS-CoV-2 seropositivity (all participants) and antibody titres (seropositive participants only), respectively. Results Of 11,130 participants, 1696 (15.2%) were seropositive. Factors independently associated with higher risk of SARS-CoV-2 seropositivity included frontline health/care occupation (aOR 1.86, 95% CI 1.48-2.33), international travel (1.20, 1.07-1.35), number of visits to shops and other indoor public places (>= 5 vs. 0/week: 1.29, 1.06-1.57, P-trend = 0.01), body mass index (BMI) >= 25 vs. < 25 kg/m(2) (1.24, 1.11-1.39), South Asian vs. White ethnicity (1.65, 1.10-2.49) and alcohol consumption >= 15 vs. 0 units/week (1.23, 1.04-1.46). Light physical exercise associated with lower risk (0.80, 0.70-0.93, for >= 10 vs. 0-4 h/week). Among seropositive participants, higher titres of anti-Spike antibodies associated with factors including BMI >= 30 vs. < 25 kg/m(2) (aGMR 1.10, 1.02-1.19), South Asian vs. White ethnicity (1.22, 1.04-1.44), frontline health/care occupation (1.24, 95% CI 1.11-1.39), international travel (1.11, 1.05-1.16) and number of visits to shops and other indoor public places (>= 5 vs. 0/week: 1.12, 1.02-1.23, P-trend = 0.01); these associations were not substantially attenuated by adjustment for COVID-19 disease severity. Conclusions Higher alcohol consumption and lower light physical exercise represent new modifiable risk factors for SARS-CoV-2 infection. Recognised associations between South Asian ethnic origin and obesity and higher risk of SARS-CoV-2 seropositivity were independent of other sociodemographic, behavioural, nutritional, clinical, and pharmacological factors investigated. Among seropositive participants, higher titres of anti-Spike antibodies in people of South Asian ancestry and in obese people were not explained by greater COVID-19 disease severity in these groups.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort
    Tribin, Felipe Echeverri
    Williams, Erin
    Testamarck, Valeska
    Carreno, Juan Manuel
    Bielak, Dominika
    Yellin, Temima
    Krammer, Florian
    Hoffer, Michael
    Pallikkuth, Suresh
    Pahwa, Savita
    PLOS ONE, 2024, 19 (04):
  • [22] Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
    Chia, Wan Ni
    Zhu, Feng
    Ong, Sean Wei Xiang
    Young, Barnaby Edward
    Fong, Siew-Wai
    Le Bert, Nina
    Tan, Chee Wah
    Tiu, Charles
    Zhang, Jinyan
    Tan, Seow Yen
    Pada, Surinder
    Chan, Yi-Hao
    Tham, Christine Y. L.
    Kunasegaran, Kamini
    Chen, Mark I-C
    Low, Jenny G. H.
    Leo, Yee-Sin
    Renia, Laurent
    Bertoletti, Antonio
    Ng, Lisa F. P.
    Lye, David Chien
    Wang, Lin-Fa
    LANCET MICROBE, 2021, 2 (06): : E240 - E249
  • [23] SARS-CoV-2 antibody response following COVID-19 vaccination, a longitudinal study
    Chavhan, Smita Santosh
    Dhikale, Prasad Tukaram
    Adsul, Balkrishna B.
    Gokhale, Chinmay N.
    Ingale, Aniket R.
    Pawar, Pradnya N.
    Jadhav, Nilam
    INDIAN JOURNAL OF COMMUNITY MEDICINE, 2023, 48 (04) : 539 - 543
  • [24] Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21
    Anda, Erik Eik
    Braaten, Tonje
    Borch, Kristin Benjaminsen
    Nost, Therese Haugdahl
    Chen, Sairah L. F.
    Lukic, Marko
    Lund, Eiliv
    Forland, Frode
    Leon, David A.
    Winje, Brita Askeland
    Kran, Anne-Marte Bakken
    Kalager, Mette
    Johansen, Fridtjof Lund
    Sandanger, Torkjel M.
    EUROSURVEILLANCE, 2022, 27 (13)
  • [25] SARS-CoV-2 Infection in Health Workers: Analysis from Verona SIEROEPID Study during the Pre-Vaccination Era
    Porru, Stefano
    Monaco, Maria Grazia Lourdes
    Carta, Angela
    Spiteri, Gianluca
    Parpaiola, Marco
    Battaggia, Andrea
    Galligioni, Giulia
    Ferrazzi, Beatrice
    Lo Cascio, Giuliana
    Gibellini, Davide
    Peretti, Angelo
    Brutti, Martina
    Tardivo, Stefano
    Ghirlanda, Giovanna
    Verlato, Giuseppe
    Gaino, Stefania
    Peserico, Denise
    Bassi, Antonella
    Lippi, Giuseppe
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [26] Duration of SARS-CoV-2 shedding: A population-based, Canadian study
    Phillips, Susan P.
    Wei, Xuejiao
    Kwong, Jeffrey C.
    Gubbay, Jonathan
    Schwartz, Kevin L.
    Majury, Anna
    Groome, Patti A.
    PLOS ONE, 2021, 16 (06):
  • [27] SARS-CoV-2 Infection in Cancer Patients: A Population-Based Study
    Zorzi, Manuel
    Guzzinati, Stefano
    Avossa, Francesco
    Fedeli, Ugo
    Calcinotto, Arianna
    Rugge, Massimo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [28] SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study
    Bin-Ghouth, Abdulla Salem
    Al-Shoteri, Sheikh
    Mahmoud, Nuha
    Musani, Altaf
    Baoom, Nasser Mohsen
    Al-Waleedi, Ali Ahmed
    Buliva, Evans
    Aly, Eman AbdelKreem
    Naiene, Jeremias Domingos
    Crestani, Rosa
    Senga, Mikiko
    Barakat, Amal
    Al-Ariqi, Lubna
    Al-Sakkaf, Khaled Zein
    Shaef, Abeer
    Thabit, Najib
    Murshed, Ahmed
    Omara, Samuel
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 115 : 239 - 244
  • [29] SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
    Husby, Anders
    Hansen, Jorgen Vinslov
    Fosbol, Emil
    Thiesson, Emilia Myrup
    Madsen, Morten
    Thomsen, Reimar W.
    Sorensen, Henrik T.
    Andersen, Morten
    Wohlfahrt, Jan
    Gislason, Gunnar
    Torp-Pedersen, Christian
    Kober, Lars
    Hviid, Anders
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 375
  • [30] Clinical impact of pulmonary arterial hypertension on SARS-CoV-2 outcomes: US pre-vaccination analysis
    Tamimi, Omar
    Ejikeme, Chidinma
    Nisar, Tariq
    Gotur, Deepa
    Safdar, Zeenat
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (08)